Labetuzumab (Anti-CEACAM5 / CEA / CD66e) is a humanised monoclonal antibody targeting carcinoembryonic antigen (CEA). It inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy. MW :145.36 KD.